MRCP Clinical Guidelines and Evidence Summary

1. Indications for MRCP

First‑line imaging for biliary and pancreatic ducts, replacing diagnostic ERCP in most scenarios – recommended by the Journal of Hepatology consensus (2017, 2022). 1
Suspected choledocholithiasis after ultrasound shows ductal dilation or when clinical suspicion remains high (elevated liver enzymes, cholestatic pattern) – MRCP is advised as the next diagnostic step. 2
Evaluation of biliary strictures to map the entire biliary tree and differentiate benign from malignant causes – endorsed by the Journal of Hepatology (2022). 3
Primary sclerosing cholangitis (PSC) – MRCP is the preferred initial diagnostic test over ERCP. 1
Failed or incomplete ERCP – MRCP should be used to reassess ductal anatomy. 2
Altered post‑surgical anatomy (e.g., hepaticojejunostomy, gastric bypass) where ERCP is technically difficult – MRCP is recommended. 2
Suspected pancreatic duct abnormalities (chronic pancreatitis, pancreatic divisum, ductal disruption) – MRCP is indicated. 4
Obstructive jaundice – MRCP determines the level and cause of obstruction. 2

Acute cholangitis requiring urgent biliary decompression – proceed directly to therapeutic ERCP. 4
MRCP‑confirmed choledocholithiasis that needs stone extraction – ERCP indicated. 2
Biliary obstruction requiring stent placement (malignant or benign strictures) – ERCP is the treatment of choice. 2
Tissue sampling (brushings/biopsies) when malignancy is suspected – ERCP required. 2
High suspicion for persistent CBD stones with ductal dilation > 6 mm or direct stone visualization – ERCP indicated. 2

Relative MRI contraindications (e.g., severe claustrophobia, inability to lie flat, extreme obesity) should be identified before MRCP. 2
Renal function assessment is only needed when gadolinium contrast is planned; standard MRCP does not require contrast. 2
Gadolinium use is unnecessary for routine MRCP; when used (e.g., for peribiliary enhancement), it is safe only if eGFR ≥ 30 mL/min/1.73 m² and a low‑dose Group II agent is selected. 2
Standard MRCP avoids gadolinium, relying on intrinsic T2 contrast from bile fluid. 2

Heavily T2‑weighted sequences generate a bright‑fluid cholangiogram without contrast injection. 2
3‑D coronal acquisitions last 3–5 minutes with respiratory triggering or breath‑hold to minimize motion artifacts. 2
Total scan time ≈ 30 minutes, longer than CT or ultrasound but eliminates radiation exposure and invasive risk. 2
Source images provide 3‑D anatomy enabling multiplanar reconstructions of the biliary and pancreatic ducts. 2

Sensitivity for common bile duct (CBD) stones: 77–88 %; specificity: 50–72 %; overall accuracy: ≈ 83 %. 5
Positive predictive value for choledocholithiasis: 87–90 %. 5
Accuracy for identifying the level of biliary obstruction: 85–100 %; detecting any obstruction: 91–100 %. 2
Sensitivity declines for stones < 4 mm, which may be missed on maximum‑intensity‑projection reconstructions. 5

False‑positive MRCP can occur when stones pass spontaneously between MRCP and confirmatory ERCP; consider the timing interval. 2
Very small stones (< 4 mm) may be missed; if clinical suspicion persists, proceed to endoscopic ultrasound (EUS) or therapeutic ERCP. 5
Early‑stage PSC limited to small intra‑hepatic ducts may be invisible on MRCP; liver biopsy is required for diagnosis. 1
Peripheral intra‑hepatic duct visualization is limited, reducing detection of early PSC or peripheral strictures. 1
Cirrhosis can produce ductal tapering that mimics pathology; correlate with clinical and laboratory data. 3

Pregnancy: MRCP is the preferred modality for obstructive jaundice, avoiding ionizing radiation; gadolinium should be avoided unless absolutely essential. 2
Pediatrics: MRI/MRCP is favored over CT to minimize radiation; sedation may be required for young children. 4
Chronic kidney disease: Standard non‑contrast MRCP is safe in all CKD stages; gadolinium should be avoided if eGFR < 30 mL/min/1.73 m² unless diagnostic benefit outweighs risk. 5

Procedural complications avoided:
- Pancreatitis (3–5 % of ERCP cases) – not seen with MRCP. 5
- Bleeding (≈ 2 % with sphincterotomy) – avoided. 5
- Cholangitis (≈ 1 %) – avoided. 5
- Procedure‑related mortality (≈ 0.4 %) – avoided. 5
Diagnostic benefits:
- Visualization of structures proximal to complete obstructions, which ERCP cannot access. 5
- Assessment of surrounding parenchyma, vessels, and lymph nodes for tumor staging (Journal of Hepatology, 2022). 3
- Evaluation of hepatic parenchyma for cirrhosis, portal hypertension, or infiltrative disease (Journal of Hepatology, 2022). 3

In patients with suspected cholangiocarcinoma, magnetic resonance cholangiopancreatography (MRCP) provides comprehensive visualization of liver and biliary anatomy, delineates local tumor extent, identifies ductal involvement, detects hepatic parenchymal abnormalities, and evaluates hilar vascular structures using MR angiography. 6

When malignancy is suspected, endoscopic retrograde cholangiopancreatography (ERCP) with brush cytology or biopsy is recommended to obtain tissue for cytologic or histologic confirmation, as the results can directly influence therapeutic decision‑making. 6

MRCP enables simultaneous assessment of surrounding hepatic parenchyma, vascular anatomy, and regional lymph nodes, allowing detection of tumor staging features such as portal vein thrombosis and hepatic metastases within a single, non‑invasive examination. 6